For treating the infarcted heart, it is currently possible to transplant myoblasts derived from a biopsy of the patient’s own muscle. This, however, requires a 3-to-4–week delay. Thus, this approach, which is described in detail in the present review article, is not only work-intensive, but involves a delay. These disadvantages could possibly be avoided by producing large batches of myoblasts from a large muscle biopsy obtained from a single donor and to transplant them to different patients following the induction of immunological tolerance obtained by transplanting hematopoietic stem cells from the same donor. It may also be possible to derive the myoblasts and the hematopoietic stem cells from a common embryonic- or adult-derived stem cell...